x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012837
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Host Species | Rabbit |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the carboxy-terminal sequence of human SHP-2. Polyclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Tyr542 and Tyr580 of human SHP-2 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PTPN11 |
| UniProt No. | Q06124 |
| Gene ID | 5781 |
| Gene Description | SHP-2 is a ubiquitously expressed, nonreceptor protein tyrosine phosphatase. It participates in signaling events downstream of receptors for growth factors, cytokines, hormones, antigens, and extracellular matrices in the control of cell growth, differentiation, migration, and death. Activation of SHP-2 and its association with Gab1 is critical for sustained Erk activation downstream of several growth factor receptors and cytokines. In addition to its role in Gab1-mediated Erk activation, SHP-2 attenuates EGF-dependent PI3 kinase activation by dephosphorylating Gab1 at p85 binding sites. SHP-2 becomes phosphorylated at Tyr542 and Tyr580 in its carboxy terminus in response to growth factor receptor activation. These phosphorylation events are thought to relieve basal inhibition and stimulate SHP-2 tyrosine phosphatase activity. Mutations in the corresponding gene result in a pair of clinically similar disorders that may result from abnormal MAPK regulation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at +4 °C short term (1-2 weeks). Store at -20 °C long term. |
| Storage Buffer | Constituent: 100% PBS |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
